Classical Hodgkin Lymphoma
Conditions
Keywords
Zimberelimab, PD-1 Checkpoint Inhibitor, AVD
Brief summary
This is a multicenter, open-label single-arm phase II study to evaluate the efficacy and safety of Zimberelimab (GLS-010) combined with AVD for newly diagnosed early-stage Hodgkin's lymphoma under the guidance of PET/CT.
Detailed description
Despite achieving good disease control and long-term survival rates for over 80% of classical Hodgkin lymphoma (cHL) patients who receive first-line therapy, approximately 10% of early-stage and 30% of advanced cHL patients experience disease relapse or refractoriness after initial treatment, and only half of the patients can be cured through high-dose therapy (HDT) and autologous stem cell transplantation (ASCT). Meanwhile, the current standard first-line treatment still centers around conventional chemotherapy with cytotoxic agents. As such, the clinical challenge of cHL first-line treatment lies in striking a balance between efficacy and toxicity, and developing low-toxicity, high-efficiency treatment strategies to achieve the optimal treatment goal of maximizing efficacy while minimizing short- and long-term toxicities.
Interventions
DRUGZimberelimab 240mg
AVD regimen: Doxorubicin 25mg/m2, d1, d15, IV; Vincristine 3mg/m2, d1, d15 IV; Dacarbazine 0.375mg/m2, d1, d15 IV
Sponsors
Guangzhou Gloria Biosciences Co., Ltd.
Sun Yat-sen University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Diagnosed with primary classical Hodgkin lymphoma (HL) based on histopathology. 2. Stage I-II . 3. At least one measurable target lesion（Lugano 2014）. 4. Age 18 years or older (including 18 years) to 45 years (recent fertility requirements and concern about chemotherapy side effects), or age \>60 years (older patients who are frail and unwilling to undergo chemotherapy), male or female. 5. ECOG PS 0-3, 6. Expected survival ≥ 3 months.
Exclusion criteria
1. Hodgkin's lymphoma with nodular lymphocyte predominant type. 2. Patients who are scheduled to undergo subsequent autologous stem cell transplantation. 3. Contraindications to radiotherapy. 4. With central nervous system (meningeal or parenchymal) involvement. 5. Contraindications to immune checkpoint inhibitors.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Complete response rate (CRR) after 2 cycles | Up to approximately 2 months | Percentage of the sum of the number of patients in complete remission (CR), complete remission without confirmation (CRu) to the total number of patients in the full analysis set |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate (ORR) after 4 cycles ( Lugano2014) | Up to approximately 2 years | ORR is proportion of subjects with complete response(CR) or partial response(PR) |
| Complete response rate (CRR) after 4 cycles ( Lugano2014) | Up to approximately 2 years | Percentage of the sum of the number of patients in complete remission (CR), complete remission without confirmation (CRu) to the total number of patients in the full analysis set |
| Total ORR and CRR after Zimberelimab treatment + radiotherapy | Up to approximately 2 years | ORR is proportion of subjects with complete response(CR) or partial response(PR); Percentage of the sum of the number of patients in complete remission (CR), complete remission without confirmation (CRu) to the total number of patients in the full analysis set |
| Overall survival (OS) | Up to approximately 2 years | Overall survival (OS) is defined as the time from the first dose of investigational products until death due to any cause |
| Progression-free survival time (PFS) | Up to approximately 2 years | Progression-free survival (PFS) is defined as the time from the first dose of investigational products until documentation of PD or death due to any cause, whichever occurs first |
| Incidence and severity of adverse events(AEs) | Up to approximately 2 years | Incidence and severity of AEs is aim to evaluate the safety of Zimberelimab(GLS-010) Combined With AVD |
| Duration of response (DOR) | Up to approximately 2 years | Duration of response (DoR) is defined as the period from the first documentation of confirmed response (CR or PR) to the first documentation of progressive disease(PD) or death due to any cause, whichever occurs first |
Countries
China
Contacts
Primary ContactZhiming Li
Backup ContactYu Wang
Outcome results
None listed